Beta Bionics Company
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
Industry:
PharmTech
Headquarters:
Boston, Massachusetts, United States
Zip:
11-50
Founded Date:
2015-10-21
Employees Number:
11-50
Funding Status:
Early Stage Venture
Acquisitions Number:
13
Investors Number:
193452916
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Series C
Last Funding Type:
admin@betabionics.org
Register and Claim Ownership